

Youxin Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2783877/publications.pdf>

Version: 2024-02-01

67
papers

1,855
citations

236925
25
h-index

289244
40
g-index

68
all docs

68
docs citations

68
times ranked

2514
citing authors

#	ARTICLE	IF	CITATIONS
1	Construction and Evaluation of Liraglutide Delivery System based on Milk Exosomes: A New Idea for Oral Peptide Delivery. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 1072-1079.	1.6	9
2	Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption. <i>Drug Delivery</i> , 2022, 29, 305-315.	5.7	9
3	A nanotherapy responsive to the inflammatory microenvironment for the dual-targeted treatment of atherosclerosis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, , 102557.	3.3	4
4	Oral delivery of liraglutide-loaded Poly-N-(2-hydroxypropyl) methacrylamide/chitosan nanoparticles: Preparation, characterization, and pharmacokinetics. <i>Journal of Biomaterials Applications</i> , 2021, 35, 754-761.	2.4	11
5	Research on the fate of polymeric nanoparticles in the process of the intestinal absorption based on model nanoparticles with various characteristics: size, surface charge and pro-hydrophobics. <i>Journal of Nanobiotechnology</i> , 2021, 19, 32.	9.1	59
6	Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: What can we learn from the literature. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 551-576.	9.1	33
7	Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 18152-18164.	8.0	14
8	PLGA/PCADK composite microspheres containing hyaluronic acid-chitosan siRNA nanoparticles: A rational design for rheumatoid arthritis therapy. <i>International Journal of Pharmaceutics</i> , 2021, 596, 120204.	5.2	16
9	Polyketal Nanoparticles Co-Loaded With miR-124 and Ketoprofen for Treatment of Rheumatoid Arthritis. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 2233-2240.	3.3	9
10	Folate receptor-targeting semiconducting polymer dots hybrid mesoporous silica nanoparticles against rheumatoid arthritis through synergistic photothermal therapy, photodynamic therapy, and chemotherapy. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120947.	5.2	17
11	Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. <i>Molecular Pharmaceutics</i> , 2021, 18, 915-927.	4.6	38
12	Folate receptor-targeting mesoporous silica-coated gold nanorod nanoparticles for the synergistic photothermal therapy and chemotherapy of rheumatoid arthritis. <i>RSC Advances</i> , 2021, 11, 3567-3574.	3.6	17
13	Study of double-targeting nanoparticles loaded with MCL-1 siRNA and dexamethasone for adjuvant-induced arthritis therapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 154, 136-143.	4.3	17
14	Synthesis and Biological Application of Polylactic Acid. <i>Molecules</i> , 2020, 25, 5023.	3.8	198
15	Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease. <i>Molecules</i> , 2020, 25, 4897.	3.8	4
16	Orally delivered legumain-activated nanovehicles improve tumor accumulation and penetration for combinational photothermal-chemotherapy. <i>Journal of Controlled Release</i> , 2020, 323, 59-70.	9.9	14
17	Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers. <i>Molecular Pharmaceutics</i> , 2020, 17, 1899-1909.	4.6	8
18	Butyl stearate prolongs the drug release period of isoperidone-loaded poly (lactic-co-glycolic acid) microspheres: <i>in vitro</i> and <i>in vivo</i> investigation. <i>Molecular Medicine Reports</i> , 2019, 19, 1595-1602.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Trastuzumab-Coated Nanoparticles Loaded With Docetaxel for Breast Cancer Therapy. Dose-Response, 2019, 17, 155932581987258.	1.6	32
20	Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102017.	3.3	43
21	Thiophene Derivatives as New Anticancer Agents and Their Therapeutic Delivery Using Folate Receptor-Targeting Nanocarriers. ACS Omega, 2019, 4, 8874-8880.	3.5	18
22	Near-infrared light-responsive, pramipexole-loaded biodegradable PLGA microspheres for therapeutic use in Parkinson's disease. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 1-11.	4.3	15
23	Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases. International Journal of Pharmaceutics, 2019, 563, 228-236.	5.2	31
24	<p></p>Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications<p></p>. International Journal of Nanomedicine, 2019, Volume 14, 8819-8834.	6.7	37
25	Hyaluronic Acid Coated Acid-Sensitive Nanoparticles for Targeted Therapy of Adjuvant-Induced Arthritis in Rats. Molecules, 2019, 24, 146.	3.8	33
26	Tf ligand-receptor-mediated exenatide-Zn ²⁺ complex oral-delivery system for penetration enhancement of exenatide. Journal of Drug Targeting, 2018, 26, 931-940.	4.4	20
27	Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice. Scientific Reports, 2018, 8, 726.	3.3	50
28	Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease. Drug Delivery, 2018, 25, 143-152.	5.7	15
29	Ketoprofen and MicroRNA-124 Co-loaded poly (lactic-co-glycolic acid) microspheres inhibit progression of Adjuvant-induced arthritis in rats. International Journal of Pharmaceutics, 2018, 552, 148-153.	5.2	27
30	The use of low molecular weight protamine to enhance oral absorption of exenatide. International Journal of Pharmaceutics, 2018, 547, 265-273.	5.2	32
31	Dual-functional lipid polymeric hybrid pH-responsive nanoparticles decorated with cell penetrating peptide and folate for therapy against rheumatoid arthritis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 39-47.	4.3	46
32	Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. International Journal of Nanomedicine, 2018, Volume 13, 1831-1840.	6.7	41
33	Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Delivery, 2018, 25, 1372-1383.	5.7	70
34	Validated LC-MS/MS method for the simultaneous determination of rotigotine and its prodrug in rat plasma and an application to pharmacokinetics and biological conversion in vitro. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 24-28.	2.8	12
35	Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. European Journal of Pharmaceutical Sciences, 2017, 96, 530-541.	4.0	31
36	Development of near zero-order release PLGA-based microspheres of a novel antipsychotic. International Journal of Pharmaceutics, 2017, 516, 32-38.	5.2	19

#	ARTICLE	IF	CITATIONS
37	Cyclic hexapeptide-conjugated nanoparticles enhance curcumin delivery to glioma tumor cells and tissue. International Journal of Nanomedicine, 2017, Volume 12, 5717-5732.	6.7	20
38	Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis. International Journal of Nanomedicine, 2017, Volume 12, 6735-6746.	6.7	79
39	Role of Four Different Kinds of Polyethylenimines (PEIs) in Preparation of Polymeric Lipid Nanoparticles and Their Anticancer Activity Study. Journal of Cancer, 2016, 7, 872-882.	2.5	26
40	Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. International Journal of Nanomedicine, 2016, Volume 11, 6547-6559.	6.7	144
41	Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles. Biomaterials Science, 2016, 4, 1219-1232.	5.4	8
42	Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration. International Journal of Pharmaceutics, 2016, 501, 112-123.	5.2	24
43	Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. International Journal of Pharmaceutics, 2016, 497, 78-87.	5.2	73
44	Application of hot-melt extrusion technology for designing an elementary osmotic pump system combined with solid dispersion for a novel poorly water-soluble antidepressant. Pharmaceutical Development and Technology, 2016, 21, 1006-1014.	2.4	4
45	Preparation and in vivo evaluation of PCADK/PLGA microspheres for improving stability and efficacy of rhGH. International Journal of Pharmaceutics, 2015, 495, 924-931.	5.2	13
46	Preparation of a mixed-matrix hydrogel of vorinostat for topical administration on the rats as experimental model. European Journal of Pharmaceutical Sciences, 2015, 78, 255-263.	4.0	6
47	The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles. Pharmaceutical Research, 2015, 32, 1017-1027.	3.5	32
48	Stabilization of Human Immunoglobulin G Encapsulated within Biodegradable Poly (Cyclohexane-1,4-Diol) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Protein and Peptide Letters, 2015, 22, 963-971.	0.9	2
49	Improving Protein Stability and Controlling Protein Release by Adding Poly (Cyclohexane -1, 4 -Diyl) Tj ETQq1 1 0.784314 rgBT /Overlock 1.6	1.6	14
50	Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation. European Journal of Pharmaceutical Sciences, 2014, 60, 40-48.	4.0	25
51	Preparation and characterization of sustained-release rotigotine film-forming gel. International Journal of Pharmaceutics, 2014, 460, 273-279.	5.2	24
52	Acylation of Exenatide by Glycolic Acid and its Anti-Diabetic Activities in db/db Mice. Pharmaceutical Research, 2014, 31, 1958-1966.	3.5	12
53	Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. International Journal of Pharmaceutics, 2014, 471, 322-331.	5.2	14
54	The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats. PLoS ONE, 2014, 9, e91775.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Stability of exenatide in poly(d,l-lactide-co-glycolide) solutions: A simplified investigation on the peptide degradation by the polymer. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 502-510.	4.0	19
56	Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres. <i>International Journal of Pharmaceutics</i> , 2013, 454, 344-353.	5.2	28
57	Enhancement of bioavailability by formulating rhEPO ionic complex with lysine into PEG-PLA micelle. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	1.9	3
58	Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. <i>International Journal of Pharmaceutics</i> , 2013, 454, 532-538.	5.2	12
59	A novel approach to medical countermeasures against organophosphorus compound toxicity. <i>Biomedical Reports</i> , 2013, 1, 901-906.	2.0	3
60	Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder. <i>Journal of Microencapsulation</i> , 2013, 30, 116-123.	2.8	2
61	Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats. <i>Pharmaceutical Research</i> , 2012, 29, 2367-2376.	3.5	37
62	Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. <i>International Journal of Pharmaceutics</i> , 2012, 427, 284-292.	5.2	56
63	Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. <i>Pharmaceutical Development and Technology</i> , 2011, 16, 377-384.	2.4	31
64	Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. <i>International Journal of Pharmaceutics</i> , 2010, 397, 44-49.	5.2	19
65	Studies on the Acute Toxicity, Pharmacokinetics and Pharmacodynamics of Paliperidone Derivatives – Comparison to Paliperidone and Risperidone in Mice and Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 656-662.	2.5	14
66	Effects of Formulation Parameters on Encapsulation Efficiency and Release Behavior of Risperidone Poly(D,L-lactide-co-glycolide) Microsphere. <i>Chemical and Pharmaceutical Bulletin</i> , 2009, 57, 1251-1256.	1.3	54
67	Biodegradable PLGA microsphere for the controlled release of tolterodine derivative. <i>Journal of Biotechnology</i> , 2008, 136, S416-S417.	3.8	4